Interstitial Pneumonitis in a Patient with Chronic Myeloid Leukemia

Imatinib–induced interstitial pneumonitis successfully switched to nilotinib in a patient with prior history of Mycobacterium tuberculosis infection

“…ILD is a rare adverse event associated with IM therapy. Few case series have been reported [ 2 , 3 , 4 , 5 ]. In the present case, the diagnosis of IM-induced ILD was made based on history, clinical symptoms, radiological findings, and pathological results.…”

Imatinib mesylate in the management of chemotherapy-induced pulmonary toxicity: a double-edged sword

“…On the other hand, although not frequent, it was shown that IM can also induce pneumonitis in patients with CML [6][7][8]. In the study by Ohnishi et al [9], among 5500 patients receiving IM, there were 27 cases of interstitial lung disease.…”

“…Surgery is the preferred therapy if the metastases are resectable, and chemotherapy is an option when surgery is not feasible. The drugs used at relapse are usually gemcitabine and docetaxel [response rates (RR) 15-30%] [5][6][7], high-dose ifosfamide [RR 30-40%] [8,9] or etoposide.…”

Chronic myeloid leukaemia and the use of tyrosine kinase inhibitors in the days of COVID‐19 pandemic

“…If severe cytopenias occur, this may hypothetically increase the risk of severe COVID‐19. In addition to that, TKI‐induced pulmonary diseases 8–10 may result in dismal outcomes of the COVID‐19. Having said that, CML‐CP patients do not appear at a higher risk of getting COVID‐19, although data are still limited.…”